PR NEWS Logo
Home
PR NewsWire
NewsWire Today
MarketWire
Submit Your Feeds
Business News
•
PR NewsWire
• Hansa Biopharma Interim Report January-June 2019
Hansa Biopharma Interim Report January-June 2019
Hansa Biopharma Interim Report January-June 2019
MALMÖ, Sweden, July 18, 2019 /PRNewswire/ -- Imlifidase benefits highlighted in recent ATC presentations. Expansion outside transplantation with initiation of study in Guillain-Barré Syndrome (GBS) continues. Highlights for the second quarter 2019 - At the 2019 American Transplant...
View More :
https://www.prnewswire.com:443/news-releases/hansa-biopharma-interim-report-januaryjune-2019-300887235.html
Releted News by prnewswire
GHP Financial Group erwirbt Vostok-Projekt
Electrolux Q2 Interim Report 2019: Good Price Momentum and Focus on Innovation
Hansa Biopharma Interim Report January-June 2019
MYM's Joint Venture Company BioHemp Completes Planting of CBD-Rich Hemp on 50-Acre Farm in McBride, British Columbia